專任教師 – 細菌學

高正彥副教授
Cheng-Yen Kao

  • 微生物及免疫學研究所 副教授
  • 專長領域 : 細菌抗藥性機制; 細菌基因體學; 毒力因子與細菌致病機制; 基因調控與轉錄體學; 小鼠細菌感染模式; 抗生素與益生菌開發
  • 辦公室位置: 生物醫學大樓(R407)
  • TEL (辦公室): +886-2-28267112
  • TEL (實驗室): +886-2-28267000 ext 65624
  • E-mail: kaocy@nycu.edu.tw
  • web site: https://sites.google.com/view/kaolab
  • ORCID: 0000-0001-8782-3912

 

學歷

國立成功大學基礎醫學研究所
國立成功大學  分子醫學研究所碩士
國立成功大學  基礎醫學研究所博士
國立陽明大學 博士後研究員
University of Wisconsin-Madison博士後研究員

經歷

2025/01~美國微生物學會駐台大使. 
2024/02~國立陽明交通大學微生物及免疫學研究所副教授.
2023/08~國立陽明交通大學醫學院微菌中心副主任
2023/01~社團法人台灣檢驗及品保學會第5屆理事
2023/01~台灣微菌聯盟第二屆秘書長
2023/01~台灣微生物學會第24屆秘書長
2020-2023. 社團法人台灣檢驗及品保學會第4屆副秘書長.
2019-2021. 美國微生物學會駐台灣青年大使. 
2019-2022. 台灣微生物學會第23屆副秘書長.
2019/08-2024/01. 國立陽明交通大學微生物及免疫學研究所副教授.

獲獎 

  1. Emergence of extensively-drug-resistant hypervirulent Acinetobacter baumannii isolated from patients with bacteraemia: bacterial phenotype and virulence analysis，刊登於International Journal of Antimicrobial Agents，獲選陽明交通大學113年第4季 (10-12月) 重要論文
  2. Outstanding Teaching Award (National Yang Ming Chiao Tung University). 112學年度陽明交通大學教學傑出教師.
  3. 2023 National Yang Ming Chiao Tung University Research Reward Subsidies (2023 Aug to 2025 Jul). 2023年陽明交通大學特殊優秀教研人員獎勵
  4. Excellent Teaching Award (College of Life Sciences). 110學年度生命科學院教學優良教師.
  5. Phylogenetic Distribution of CRISPR-Cas Systems in Staphylococcus lugdunensis，刊登於Microbiology Spectrum，獲選陽明交通大學110年第4季 (10-12月) 重要論文
  6. Outstanding alumni, Department of Biochemical Science and Technology, National Chia-Yi University. 嘉義大學生化科技學系108年度傑出系友.

研討會主持人/主辦人

  1. 2025 Mar 22th. (Invited talk & Modulator). Culturomics: The bottleneck in validating a strain’s role in microbiota research and product development. The 8th Annual Conference of Taiwan Microbiota Consortium(2025 ACTMC) & The 3rd Annual Conference of Asia Pacific Microbiota Consortium. National Taiwan University Hospital.
  2. 2024 Oct 5th. (Moderator). 第一屆微生物組和以微生物組為基礎的治療學研討會 1st Symposium on Microbiome and Microbiome-Based Therapeutics (SMMT). Conference rooms, Research Building, 1st Floor, Chang Gung Memorial Hospital, Taiwan.
  3. 2022 Aug 25th-27th. Committee Chair – 26th Bacteriology conference. 2022台灣第26屆細菌學研討會.National Yang Ming Chiao Tung University, HsinChu, Taiwan.
  4. 2019 Aug 31st. Committee Chair – Hot topics in the 119th ASM General Meeting-細菌診斷與抗藥性新知研討會 (Co-hosted by ASM, TSM, and NYMU) National Yang-Ming University.

國際邀請演講 

  1. Apr 8th. (Invited talk). Diversity of virulence plasmids and phenotypes in carbapenem-resistant Klebsiella pneumoniae and liver abscess-associated Klebsiella pneumoniae. 2025 International Symposium on Molecular Sciences. University of Santo Tomas, Manila, Philippins.
  2. 2025 Mar 22th. (Invited talk & Modulator). Culturomics: The bottleneck in validating a strain’s role in microbiota research and product development. The 8th Annual Conference of Taiwan Microbiota Consortium(2025 ACTMC) & The 3rd Annual Conference of Asia Pacific Microbiota Consortium. National Taiwan University Hospital.
  3. 2025 Jan 11th. (Invited talk). From Biomarkers to Genomics: Decoding Virulence and Plasmids in Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae. Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya.
  4. 2024 Aug 15th. (Invited talk). Integrating Fundamental and Applied Microbiology Research to Tackle Urgent Clinical Treatment Challenges. Nanotechnology & Catalysis Research Centre (NANOCAT), Universiti Malaya.
  5. 2023 July 6th-8th. In Vivo Evolution of Escherichia coli and Recurrent Urinary Tract Infections. (Invited talk). 19th The Asia Pacific Congress of Clinical Microbiology & Infection (APCCMI) Seoul, Korea.
  6. 2023 May 3rd. Characterization of the in vivo evolution of pathogens isolated from patients with recurrent urinary tract infections. (Invited talk). PROGRAMME 1ST INTERNATIONAL SCIENTIFIC CONFERENCE ON MICROBIOLOGY-2023. Ulaanbaatar city, Mongolia.
  7. 2019 Aug 31st. New pipeline drugs for post-antibiotic era. (Conference invited talk). Hot topics in the 119th ASM General Meeting-2019細菌診斷與抗藥性新知研討會. National Yang-Ming University, Taipei, Taiwan.
  8. Sep 30th. A novel screen suggests that regulation of fermentation is critical for cytosolic survival and virulence of Listeria monocytogenes. (Conference invited talk). 25th Annual Midwest Microbial Pathogenesis Conference, University of Iowa, Iowa, IA (MMPC).

論文

2025:

  • Optimization and spectrum characterization of the antibacterial activity of lugdunin. Kao CY,Longjama N, Hidrosollo JH, Lin LC, Lu JJ. International Journal of Medical Microbiology. (In revision).
  • Hha of the toxin-antitoxin system regulates diverse phenotypes of uropathogenic Proteus mirabilis Chao YJ, Lee YJ, Chen HH, Kao CY, Liaw SJ. J Microbiol Immunol Infect. (In revision).
  • Isolation and characterization of lytic bacteriophage against carbapenem-resistant Enterobacter cloacae Kuo HY, Bregente CJB, Thuy TTD, Hidrosollo JH, Cruz-Papa DMD, Gutierrez TA, Huang YT, Chuang YJ, Hsueh PR, Kao CY.Microbiology Spectrum. (In revision).
  • Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coliin recurrent and multi-site infections. Cheng YY, Tsai YM, Chuang YC, Fan YH, Wang MC, Chen YC, Teng CH, Kuo PY, Thuy TTD, Bregente CJB, Zhang YZ, Lee YH, Ho DZ, Kao CY.  Gut pathogens. (In revision).
  • Rising threat of metallo-β-lactamase-producing Klebsiella oxytoca complex in Taiwan. 2013-2022. Huang YT, Bregente CJB, Liao CH, Kuo YW, Lee TF, Kao CY*,Hsueh PR*. (*equal contribution). Int J Antimicrob Agents. 2025 Aug;66(2):107515. doi: 10.1016/j.ijantimicag.2025.107515. (SCI, IF: 4.6, Ranking: 17/137 Infectious Diseases).
  • Indolenine-substituted pyrazole derivative 4e inhibits planktonic Staphylococcus lugdunensisgrowth and biofilm formation by disrupting purine biosynthesis and cell wall integrity. Hidrosollo JH, Liao HW, Yap CH, James JJ, Lu JJ, Tai YH, Wei CC, Thuy TTD, Chin SP, Tay ST*, Chee CF*, Kao CY*. (*equal contribution). Antimicrob Agents Chemother. 2025 Jul 23:e0019925. doi: 10.1128/aac.00199-25. (SCI, IF: 4.5, Ranking: 64/352 Pharmacology & Pharmacy). 
  • Regulatory Networks in Helicobacter pylori: The Roles of Two-Component Systems and CsrA in Stress Adaptation. Kuo PY, Kao CY.J Microbiol Immunol Infect. J Microbiol Immunol Infect. 2025 Jul 1:S1684-1182(25)00132-X. doi: 10.1016/j.jmii.2025.06.009. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Study of lug operon, SCCmecelements, antimicrobial resistance, MGEs and STs of Staphylococcus lugdunensis clinical isolates through whole-genome sequencing. Chang TY, Lin LC,  Kao CY. Lu JJ. Int J Mol Sci. 2025 Jun 25;26(13):6106. doi: 10.3390/ijms26136106. (SCI, IF: 4.9, Ranking: 72/319 Biochemistry & Molecular biology).
  • Compositional and metabolomic shifts of the gut microbiome in alcohol-related liver disease. Kuo CH, El-Omar EM, Kao CY, Lin JT, Wu CY. Journal of Gastroenterology and Hepatology. J Gastroenterol Hepatol. 2025 Jun 24. doi: 10.1111/jgh.17038. (SCI, IF: 3.4, Ranking: 47/147 Gastroenterology & Hepatology).
  • The development of live biotherapeutic products: A position statement of Asia-Pacific Microbiome Consortium. Tseng CH, Wong SH, Yu J, Lee YY, Terauchi J, Lai HC, Luo JC, Kao CY,Yu SL, Liou JM, Wu DC, Hou MC, Wu MS, Wu JJ, Sung JJY, El-Omar EM, Wu CY. Gut. 2025 Apr 7;74(5):706-713. doi: 10.1136/gutjnl-2024-334501. (SCI, IF: 25.8, Ranking: 4/147 Gastroenterology & Hepatology).
  • O-antigen of uropathogenic Escherichia coli is required for induction of neutrophil extracellular traps. Lin WH, Sheu SM, Wu CF, Huang WC, Hsu LJ, Yu KC, Cheng HC, Kao CY, Wu JJ, Wang MC, Teng CH. J Microbiol Immunol Infect. 2025 Apr;58(2):209-218. doi: 10.1016/j.jmii.2024.12.007. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • An Integrated Platform for Investigating Drug-Microbial Interactions to Support Pharmacomicrobiomics Studies. Tai YH*, Kao CY*, Zhang YP, Chiou YJ, Chiu HH, Thuy TTD, Liao HW. (*equal contribution). Talanta. 2025 Feb 1;283:127094. doi: 10.1016/j.talanta.2024.127094. Epub 2024 Oct 24. (SCI, IF: 6.1, Ranking: 14/111 Chemistry, Analytical).
  • Antibacterial effects and mechanism of action of Low Energy Shock Waves on uropathogenic  coliinvestigated by in vitro and in vivo cystitis rat model. Wu ZS, Kao CY, Wang HJ, Lee WC, Luo HL, Huang CC, Chuang YC. Int Urol Nephrol. 2025 Jan;57(1):49-61. doi: 10.1007/s11255-024-04173-8. (SCI, IF: 1.9, Ranking: 69/133 Urology & Nephrology).

2024:

  • Molecular characterization of colistin-resistant Klebsiella pneumoniaeisolates and their conjugative mcr-carrying plasmids. Kao CY*, Kuo PY*, Lin CC, Cheng YY, Wang MC, Chen YC, Lin WH. (*equal contribution). J Infect Public Health. 2024 Dec;17(12):102588. doi: 10.1016/j.jiph.2024.102588. Epub 2024 Nov 7. (SCI, IF: 4.0, Ranking: 57/419 Public, Environmental & Occupational Health). 
  • Emergence of extensively drug-resistant hypervirulent Acinetobacter baumanniiisolated from patients with bacteremia: bacterial phenotype and virulence analysis. Chen PK, Liu CY, Kuo HY, Lee YT, Liu YH, Zhang YZ, Kao CY. Int J Antimicrob Agents. 2024 Dec;64(6):107358. doi: 10.1016/j.ijantimicag.2024.107358. (SCI, IF: 4.6, Ranking: 17/137 Infectious Diseases).
  • Defect Engineered Bi2Te3 Nanosheets with Enhanced Haloperoxidase Activity for Marine Antibiofouling. Kulkarnia SS, Tong DK, Wu CT, Kao CY, Chattopadhyaya S. 2024. Small. 2024 Oct;20(43):e2401929. doi: 10.1002/smll.202401929. (SCI, IF: 12.1, Ranking: 14/187 Physics, Applied). 
  • First report of the chromosomal integration of carbapenemase gene blaIMP-19 in Acinetobacter baumanniiAB322: the legacy of integron in phage-plasmid? Shih YL, Bregente CJB, Chen PK, Thuy TTD, Chen YC, Kuo HY, Lu HF, Kao CY. Microbiol Spectr. 2024 Jun 4;12(6):e0038224. doi: 10.1128/spectrum.00382-24. (SCI, IF: 3.8, Ranking: 58/163 Microbiology).
  • Peptidoglycan endopeptidase MepM of uropathogenic Escherichia colicontributes to competitive fitness during urinary tract infections. Huang WC, Dwija IBNP, Hashimoto M, Wu JJ, Wang MC, Kao CY, Lin WH, Wang S, Teng CH. BMC Microbiol. 2024 May 30;24(1):190. doi: 10.1186/s12866-024-03290-9. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • A 19-year longitudinal study to characterize carbapenem-nonsusceptible Acinetobacter isolated from patients with bloodstream infections and the contribution of conjugative plasmids to carbapenem resistance and virulence. Chen PK*, Lee YT*, Liu CY*, Anh K, Thuy TTD, Wu JJ, Liao CH, Huang YT, Chen YC, Kao CY. (*equal contribution). J Microbiol Immunol Infect. 2024 Apr;57(2):288-299. doi: 10.1016/j.jmii.2024.01.008. Epub 2024 Feb 8. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Molecular characterization of lugdunin inactivation mechanisms and their association with Staphylococcus lugdunensisgenetic types. Lin LC*, Kao CY*, Chang SC, Hidrosollo JH, Lu JJ. (*equal contribution). J Microbiol Immunol Infect. 2024 Apr;57(2):278-287. doi: 10.1016/j.jmii.2024.01.005. Epub 2024 Jan 20. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Characterization of the broad-spectrum antibacterial activity of bacteriocin-like inhibitory substance-producing probiotics isolated from fermented foods. Thuy TTD*, Lu HF*, Bregente CJB, Huang FCA, Tu PC, Kao CY. BMC Microbiol. 2024 Mar 11;24(1):85. doi: 10.1186/s12866-024-03245-0. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • A longitudinal epidemiology study of fluoroquinolone-nonsusceptible Klebsiella pneumoniaereveals an increasing prevalence of qnrB and qnrS in Taiwan. Kuo PY*, Lin WH*, Tang SF, Cheng YY, Bregente CJB, Duong TTT, Wang MC, Teng CH, Hsieh YH, Tsai PF, Li YC, Kao CY. (*equal contribution). J Infect Public Health. 2024 Mar;17(3):457-463. doi: 10.1016/j.jiph.2024.01.005. (SCI, IF: 4.0, Ranking: 57/419 Public, Environmental & Occupational Health). 

2023:

  • Characterization of uropathogenic Escherichia coli phylogroups associated with antimicrobial resistance, virulence factor distribution, and virulence-related phenotypes. Wang MC*, Fan YH*, Zhang YZ, Bregente CJB, Lin WH, Lin TP, Chen CA, Kao CY.(*equal contribution). Infect Genet Evol. 2023 Oct;114:105493. doi: 10.1016/j.meegid.2023.105493. (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).
  • Lugdunin production and activity in Staphylococcus lugdunensisbloodstream isolates are associated with its genotypes. Chang SC*, Kao CY*, Lin LC, Hidrosollo JH, Lu JJ. (*equal contribution). Microbiol Spectr. 2023 Sep 21;11(5):e0129823. doi: 10.1128/spectrum.01298-23. (SCI, IF: 3.8, Ranking: 58/163 Microbiology).
  • A 24-year longitudinal study of Klebsiella pneumoniaeisolated from patients with bacteremia and urinary tract infections reveals the association between capsular serotypes, antibiotic resistance, and virulence gene distribution. Kao CY, Zhang YZ, Bregente CJB, Kuo PY, Chen PK, Chao JY, Duong TTT, Wang MC, Thuy TTD, Hidrosollo JH, Tsai PF, Li YC, Lin WH. Epidemiol Infect. 2023 Sep 7;151:e155. doi: 10.1017/S0950268823001486. (SCI, IF: 2.2, Ranking: 183/419 Public, Environmental & Occupational Health).
  • Melatonin acts synergistically with pazopanib against renal cell carcinoma cells through p38 MAPK-mediated mitochondrial and autophagic apoptosis. Lai CP, Chen YS, Ying TH, Kao CY, Chiou HL, Kao SH, Hsieh YH. Kidney Res Clin Pract. 2023 Jul;42(4):487-500. doi: 10.23876/j.krcp.22.114. (SCI, IF: 3.8, Ranking: 21/133 Urology & Nephrology).
  • Sequential isolation of metabolites and lipids for the same sample to achieve multiomics by using TRIzol reagent. Kao CY*, Chang CT*, Kuo PY, Lin CJ, Chiu HH, Liao HW. (*equal contribution). Talanta. 2023 Jun 1:258:124416. doi: 10.1016/j.talanta.2023.124416. (SCI, IF: 6.1, Ranking: 14/111 Chemistry, Analytical).
  • Genome-based characterization of conjugative IncHI1B plasmid carrying carbapenemase genes blaVIM-1, blaIMP-23, and truncated blaOXA-256 in Klebsiella pneumoniae Wen LL, Kuo PY, Thuy TTD, Duong TTT, Huang YT, Hseuh PR, Chen YC, Kao CY.Infect Genet Evol. 2023 Jun;110:105420. doi: 10.1016/j.meegid.2023.105420. (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).
  • Characterization of oxacillin-resistant Staphylococcus lugdunensisisolated from sterile body fluids in a medical center in Taiwan: a 12-year longitudinal epidemiological study. Chang SC, Hidrosollo JH, Lin LC, Ou YH, Kao CY*, Lu JJ*. (*equal contribution). J Microbiol Immunol Infect. 2023 Apr;56(2):292-298. doi: 10.1016/j.jmii.2022.08.021. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Characterization of host and Escherichia colistrains causing recurrent urinary tract infections based on molecular typing. Kao CY, Zhang YZ, Yang DC, Chen PK, Teng CH, Lin WH, Wang MC. BMC Microbiol. 2023 Mar 30;23(1):90. doi: 10.1186/s12866-023-02820-1. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • Licochalcone A Suppresses Renal Cancer Cell Proliferation and Metastasis by Engagement of Sp1-Mediated LC3 Expression. Tseng TY, Lee CH, Lee HL, Su CY, Kao CY, Tsai JP, Hsieh YH. Pharmaceutics. 2023 Feb 17;15(2):684. doi: 10.3390/pharmaceutics15020684. (SCI, IF: 5.5, Ranking: 34/352 Pharmacology & Pharmacy). 

2022:

  • Anti-Helicobacter pyloriactivity of potential probiotic Lactiplantibacillus pentosus Thuy TTD, Kuo PY, Lin SM, Kao CY. BMC Microbiol. 2022 Nov 21;22(1):277.  doi: 10.1186/s12866-022-02701-z. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • Heparin is required for the formation of granules in connective tissue mast cells. DzhagalovI, Herrera-Heredia SA, Hsu HP, Kao CY, Tsai YH, Yamaguchi Yu, Roers A, Hsu CL. Front Immunol. 2022 Nov 9;13:1000405. doi: 10.3389/fimmu.2022.1000405. (SCI, IF: 5.9, Ranking: 32/183 Immunology).
  • Plasmid-mediated quinolone resistance determinants in fluoroquinolone-nonsusceptible Escherichia coliisolated from patients with urinary tract infections in a university hospital in Taiwan, 2009-2010 and 2020. Kuo PY, Lo YT, Chiou YJ, Chen CA, Hidrosollo JH, Thuy TTD, Zhang YZ, Wang MC, Lin TP, Lin WH*, Kao CY*. (*equal contribution). J Glob Antimicrob Resist. 2022 Sep;30:241-248. doi: 10.1016/j.jgar.2022.06.004. (SCI, IF: 3.2, Ranking: 43/137 Infectious Diseases).
  • Whole-genome-sequence-based characterization of an extensively drug-resistant uropathogenic Escherichia coli Thuy TTD*, Lu HF*, Kuo PY*, Lin WH, Lin TP, Lee YZ, Duong TTT, Wang MC, Lee YH, Wen LL, Chen YC, Kao CY.(*equal contribution). BMC Microbiol. 2022 Jun 6;22(1):150.  doi:10.1186/s12866-022-02562-6 (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • Uremic Toxin Producing BacteroidesSpecies Prevail the Gut Microbiota of Taiwanese CKD patients: An analysis using a new Taiwan Microbiome Baseline. Shivani S*, Kao CY*, Amrita C, Chen JW, Lai LC, Lin WH, Lu TP, Huang IH, Tsai MH, Teng CH, Wu JJ, Hsieh YH, Wang MC, Chuang EC. (*equal contribution). Front Cell Infect Microbiol. 2022 Apr 26;12:726256. doi: 10.3389/fcimb.2022.726256 (SCI, IF: 4.8, Ranking: 32/163 Microbiology).
  • Escherichia coliurinary tract infections: host age-related differences in bacterial virulence factors and antimicrobial susceptibility. Lin WH, Wang MC, Liu PY, Chen PS, Wen LL, Teng CH, Kao CY. J Microbiol Immunol Infect.  2022 Apr;55(2):249-256. doi: 10.1016/j.jmii.2021.04.001. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Accurate Detection of Oxacillin-Resistant Staphylococcus lugdunensisby Use of Agar Dilution. Kao CY*, Wu HH*, Chang SC, Lin LC, Liu TP,  Lu JJ. (*equal contribution). J Microbiol Immunol Infect. 2022 Apr;55(2):234-240. doi: 10.1016/j.jmii.2021.02.009. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • A longitudinal 9-year study of the molecular epidemiology of carbapenem-resistant Enterobacteriaceae isolated from a regional hospital in northern Taiwan: Predominance of carbapenemase KPC-2 and OXA-48. Duong TTT*, Tsai YM*, Wen LL, Chiu HC, Chen PK, Thuy TTD, Kuo PY, Hidrosollo JH, Wang S, Zhang YZ, Lin WH, Wang MC, Kao CY. (*equal contribution). Front Microbiol. 2022 Mar 11;13:703113. doi: 3389/fmicb.2022.703113(SCI, IF: 4.5, Ranking: 38/163 Microbiology). 

2021:

  • Phylogenetic Distribution of CRISPR-Cas Systems in Staphylococcus lugdunensis.Kao CY*, Lu JJ*, Lin LC, Lin HC, Chang SC. (*equal contribution). Microbiol Spectr. 2021 Dec 22;9(3):e0124721. doi: 10.1128/spectrum.01247-21. (SCI, IF: 3.8, Ranking: 58/163 Microbiology).
  • Untargeted Microbial Exometabolomics and Metabolomics Analysis of Helicobacter pylori J99 and jhp0106Kao CY, Kuo PY, Liao HW. Metabolites. 2021 Nov;11(12), 808; doi:10.3390/metabo11120808. (SCI, IF: 3.47, Ranking: 124/319 Biochemistry & Molecular biology)
  • Distinct Characteristics of Escherichia coliIsolated from Patients with Urinary Tract Infections in a Medical Center at A Ten-Year Interval. Lin WH*, Zhang YZ*, Liu PY*, Chen PS, Wang S, Kuo PY, Thuy TTD, Duong TTT, Wen LL, Hsieh YH, Wang MC, Kao CY. (*equal contribution). Pathogens. 2021 Sep 8;10(9):1156. doi: 10.3390/pathogens10091156 (SCI, IF: 3.3, Ranking: 74/163 Microbiology)
  • Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori. Yang KY*, Kao CY*, Su SW Marcia*, Wang S, Chen YL, Hu ST, Chen JW, Teng CH, Tsai PJ, Wu JJ. (*equal contribution). Helicobacter. 2021 Apr;26(2):e12787. doi: 10.1111/hel.12787. Epub 2021 Feb 15. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology) 

2020:

  • Combination of modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) for phenotypic detection of carbapenemase-producing Enterobacteriaceae. Tsai YM, Wang S, Chiu HC, Kao CY*, Wen LL*. (*equal contribution). BMC Microbiol. 2020 Oct 17;20(1):315. doi: 10.1186/s12866-020-02010-3. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • Defeating antibiotic-resistant bacteria: exploring alternative drug targets for a post-antibiotic era. Wang CH, Hsieh YH, Zach P, Kao CY. Int J Mol Sci. 2020 Feb 5;21(3). pii: E1061. doi: 10.3390/ijms21031061. (SCI, IF: 4.9, Ranking: 72/319 Biochemistry & Molecular biology)

2019:

  • Mutation of the transcriptional regulator YtoI rescues Listeria monocytogenes mutants deficient in the essential shared metabolite 1,4-dihydroxy-2-naphthoate (DHNA). Chen GY*, Kao CY*, Smith H, Rust D, Zach P, Li AY, Sauer JD. (*equal contribution). Infect Immun. 2019 Dec 17;88(1). pii: e00366-19. doi: 10.1128/IAI.00366-19. (SCI, IF: 2.8, Ranking: 57/137 Infectious disease)
  • Fermented soymilk and soy and cow milk mixture, supplemented with orange peel fiber or Tremellaflava fermented powder as prebiotics for high EPS-producing Lactobacillus pentosus SLC 13. Huang ML, Huang JY, Kao CY, Fang TJ. J Sci Food Agric. 2019 Jul;99(9):4373-4382. doi: 10.1002/jsfa.9671. (SCI, IF: 3.5, Ranking: 18/94 Agriculture, Multidisciplinary)

2018:

  • Characterization of CRISPR-Cas systems in Clinical Klebsiella pneumoniaeIsolates Uncovers its Potential Association with Antibiotic Susceptibility. Li HY*, Kao CY*, Lin WH, Zheng PX, Yan JJ, Wang MC, Teng CH, Wu JJ. (*equal contribution). Front Microbiol. 2018 Jul 16;9:1595. doi: 10.3389/fmicb.2018.01595. (SCI, IF: 4.5, Ranking: 38/163 Microbiology). 
  • Comparative Genomics of Escherichia coliSequence Type 219 Clones from the Same Patient: Evolution of the IncI1 blaCMY-Carrying Plasmid in Vivo.  Kao CY, Chen JW, Liu TL, Yan JJ, Wu JJ. Front Microbiol. 2018 Jul 16;9:1518. doi: 10.3389/fmicb.2018.01518. (SCI, IF: 4.5, Ranking: 38/163 Microbiology). 
  • Complete genome sequence of Lactobacillus pentosusSLC13, isolated from mustard pickles, a potential probiotic strain with antimicrobial activity against foodborne pathogenic microorganisms. Huang ML, Huang JY, Kao CY, Fang TJ. Gut Pathog. 2018 Jan 18;10:1. doi: 10.1186/s13099-018-0228-y. eCollection 2018. (SCI, IF: 4.0, Ranking: 35/147 Gastroenterology & Hepatology)

2017: 

  • Inactivation of ferric uptake regulator (Fur) attenuates Helicobacter pylori J99 motility by disturbing the flagellar motor switch and autoinducer-2 production. Lee AY*, Kao CY*, Wang YK, Lin SY, Lai TY, Sheu BS, Lo CJ,Wu JJ. (*equal contribution). Helicobacter. 2017 Aug;22(4). doi: 10.1111/hel.12388. Epub 2017 Apr 12. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • Characterization of high exopolysaccharide-producing Lactobacillus strains isolated from mustard pickles for potential probiotic applications. Huang JY, Kao CY, Liu WS, Fang TJ. Int Microbiol. 2017 Jun;20(2):75-84. doi: 10.2436/20.1501.01.287. (SCI, IF: 2.3, Ranking: 113/177 Biotechnology and Applied Microbiology)
  • Molecular Characterization of Antimicrobial Susceptibility of SalmonellaIsolates: First Identification of a Plasmid Carrying qnrD or oqxAB in Taiwan. Kao CY*, Chen CA*, Liu YF, Wu HM, Chiou CS, Yan JJ, Wu  (*equal contribution) J Microbiol Immunol Infect. 2017 Apr;50(2):214-223. doi: 10.1016/j.jmii.2015.03.004. Epub 2015 May 14. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Complete Genome Sequence of Carbapenem-Resistant Klebsiella pneumoniaeStrain 1756, Isolated from a Pus Specimen. Kao CY, Yan JJ, Lin YC, Zheng PX, Wu JJ. Genome Announc. 2017 Mar 30;5(13). pii: e00066-17. doi: 10.1128/genomeA.00066-17.
  • The Helicobacter pyloriJ99 jhp0106 gene, under the Control of the CsrA/RpoN Regulatory System, Modulates Flagella Formation and Motility. Kao CY, Chen JW, Wang S, Sheu BS, Wu JJ. Front Microbiol. 2017 Mar 28;8:483. doi: 10.3389/fmicb.2017.00483. eCollection 2017. (SCI, IF: 4.5, Ranking: 38/163 Microbiology). 
  • Orange Peel Fiber and Tremella flavaChen Fermented Powder Effectively Induce Exopolysaccharide Production by Lactobacillus plantarum SLC 13. Huang JY, Huang ML, Kao CY, Fang TJ. Int. J. Agric. Biol. 2017. 19(3):437-444. doi: 10.17957/IJAB/15.0298. (SCI, IF: 0.822, Ranking: 38/58 Agriculture, Multidisciplinary)

2016:

  • Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coliand Klebsiella isolates in Mongolia. Kao CY, Udval U, Huang YT, Wu HM, Huang AH, Bolormaa E, Yan JJ, Urangoo Z, Batbaatar G, Khosbayar T, Wu JJ. J Microbiol Immunol Infect. 2016 Oct;49(5):692-700. doi: 10.1016/j.jmii.2015.05.009. (SCI, IF: 3.7, Ranking: 35/137 Infectious Diseases).
  • Plasmid-mediated quinolone resistance determinants in quinolone-resistant Escherichia coliisolated from patients with bacteremia in a university hospital in Taiwan, 2001-2015. Kao CY, Wu HM, Lin WH, Tseng CC, Yan JJ, Wang MC, Teng CH, Wu  Sci Rep. 2016 Aug 30;6:32281. doi: 10.1038/srep32281. (SCI, IF: 3.9, Ranking: 25/135 Multidisciplinary Sciences)
  • Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosaisolated from patients with bloodstream infection in Taiwan. Kao CY*, Chen SS*, Hung KH, Wu HM, Hsueh PR, Yan JJ, Wu  (*equal contribution) BMC Microbiol. 2016 Jun 13;16(1):107. doi: 10.1186/s12866-016-0719-2. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).
  • An integrated microfluidic system for diagnosis of the resistance of Helicobacter pylori to quinolone-based antibiotics. Chao CY, Wang CH, Che YJ, Kao CY, Wu JJ, Lee GB. Biosens Bioelectron. 2016 Apr 15;78:281-9. doi: 10.1016/j.bios.2015.11.046. (SCI, IF: 10.5, Ranking: 3/111 Chemistry, Analytical)
  • First characterization of fluoroquinolone resistance mechanisms in CTX-M-producing Escherichia colifrom Mongolia. Kao CY, Udval U, Wu HM, Bolormaa E, Yan JJ, Khosbayar T, Wu  Infect Genet Evol. 2016 Mar;38:79-81. doi:10.1016/j.meegid.2015.12.010. (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).
  • Helicobacter pylori Infection: An Overview of Bacterial Virulence Factors and Pathogenesis. Kao CY, Sheu BS, Wu JJ. Biomed J. 2016 Feb;39(1):14-23. doi: 10.1016/j.bj.2015.06.002. Epub 2016 Apr 1. (SCI, IF: 4.4, Ranking: 89/319 Biochemistry & Molecular biology)

2015: 

  • Intracellular Osteopontin Induced by CagA-positive Helicobacter pyloriPromotes Beta-catenin Accumulation and Interleukin-8 Secretion in Gastric Epithelial cells. Chang WL, Yang HB, Cheng HC, Yeh YC, Kao CY, Wu JJ, Lu CC, Sheu BS. Helicobacter. 2015 Dec;20(6):476-84. doi: 10.1111/hel.12225. Epub 2015 Mar 3.  (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • The Challenge of Fluoroquinolone Resistance: Epidemiology, Mechanisms, and Clinical impact. Kao CY, Wu JJ. J Biomed Lab Sci. 台灣生檢雜誌.2015 Sep;27(3):77-86. 
  • Carbapenem Resistance: Epidemiology, Mechanisms and Screening Methods. Kao CY, Wu JJ. J Biomed Lab Sci. 台灣生檢雜誌. 2015 Mar;27(1):1-9.
  • Genome Sequence and Annotation of Helicobacter pyloriStrain Hp238 Isolated from a Taiwanese Patient with MALT Lymphoma. Kao CY, Chen JW, Huang YT, Sheu SM, Sheu BS, Wu JJ. Genome Announc. 2015 Feb 19;3(1). pii: e00006-15. doi: 10.1128/genomeA.00006-15.

2014:  

  • CsrA regulates Helicobacter pylori J99 motility and adhesion by controlling flagella formation. Kao CY, SheuBS, Wu JJ. Helicobacter. 2014 Dec;19(6):443-54. doi: 10.1111/hel.12148. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • The Complex Interplay among Bacterial Motility and Virulence Factors in Different Escherichia coliKao CY, Lin WH, Tseng CC, Wu AB, Cheng SW, Wang MC, Wu JJ.  Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2157-62. doi: 10.1007/s10096-014-2171-2. (SCI, IF: 3.0, Ranking: 48/137 Infectious Diseases)
  • Dissemination of OXA-Carbapenemase-Producing Acinetobacter baumannii ST195 and ST642 in a Mongolian Hospital. Kao CY, UdvalU, Oyunchimeg R, Wu HM, Huang AH, Bolormaa E, Munkhtuya E, Yan JJ, Batbaatar G, Khosbayar T, Wu  Infect Genet Evol. 2014 Dec;28:313-6. doi: 10.1016/j.meegid.2014.10.024. (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).
  • Higher glucose level can enhance the pyloriadhesion and virulence related with type IV secretion system in AGS cells. Sheu SM, Cheng H, Kao CY, Yang YJ, Wu JJ, Sheu BS. J Biomed Sci. 2014 Oct 9;21(1):96. doi:10.1186/s12929-014-0096-9. (SCI, IF: 12,1, Ranking: 9/195 Medicine, Research, & Experimental)
  • Clinical and microbiologic characteristics of Klebsiella pneumonia from community-acquired recurrent urinary tract infections. Lin WH, Kao CY, Yang DC, Tseng CC. Wu AB, Teng CH, Wang MC, Wu JJ. Eur J Clin Microbiol Infect Dis. 2014 Sep;33(9):1533-9. doi: 10.1007/s10096-014-2100-4. (SCI, IF: 3.0, Ranking: 48/137 Infectious Diseases).
  • First Report of the Prevalence of Extended-Spectrum β-Lactamase Producing Escherichia coliin Two Mongolian Hospitals. Kao CY*, Udval U*, Wu HM, Bolormaa E, Yan JJ, Khosbayar T, Wu JJ. (*equal contribution) Infect Genet Evol. 2014 Jul;25:66-8. doi: 10.1016/j.meegid.2014.04.012.  (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).
  • Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment. Kao CY, Lee AY, Huang AH, Song PI, Yang YJ, Sheu SM, Chang WL, Sheu BS, Wu JJ. Infect Genet Evol. 2014 Apr;23:196-202. doi: 10.1016/j.meegid.2014.02.009. (SCI, IF: 2.6, Ranking: 63/137 Infectious Diseases).

 2012:

  • Higher motility enhances bacterial density and inflammatory response in dyspeptic patients infected with Helicobacter pylori. Kao CY, Sheu BS, Sheu SM, Yang HB, Chang WL, Cheng HC, Wu JJ. Helicobacter. 2012 Dec;17(6):411-6. doi: 10.1111/j.1523-5378.2012.00974.x. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • Gemifloxacin can partially overcome quinolone resistance of  pyloriwith gyrA mutation in Taiwan. Chang WL, Kao CY, Wu CT, Huang AH, Wu JJ, Yang HB, Cheng HC, Sheu BS. Helicobacter. 2012 Jun;17(3):210-5. doi: 10.1111/j.1523-5378.2012.00935.x. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • Length of thymidine homopolymeric repeats modulates promoter activity of sabAin Helicobacter pylori. Kao CY, Sheu SM, Sheu BS, Wu JJ. Helicobacter. 2012 Jun;17(3):203-9. doi: 10.1111/j.1523-5378.2012.00936.x. (SCI, IF: 4.3, Ranking: 34/147 Gastroenterology & Hepatology).
  • pyloriclinical isolates have diverse babAB genotype distributions over different topographic sites of stomach with correlation to clinical disease outcomes. Sheu SM, Sheu BS, Chiang WC, Kao CY, Wu HM, Yang HB, Wu JJ. BMC Microbiol. 2012 May 30;12:89. doi: 10.1186/1471-2180-12-89. (SCI, IF: 4.2, Ranking: 46/163 Microbiology).

計畫 

  • 2025/08-2026/07. Co-Principal investigator. National Science and Technology Council. Title: Investigate the impact of the microbiota and metabolism on MASLDHCC and develop probiotics or post-biotics with the potential to improve and prevent MASLD-HCC. Grant number: NSTC 114-2314-B-A49-088-.
  • 2025/08-2026/07. Co-Principal investigator. National Science and Technology Council. Title: Investigation into the evolution of carbapenem-resistant Escherichia coli within the host and its association with recurrent and multi-site infections. Grant number: NSTC 114-2635-B-385-001-.
  • 2025/05-2026/04. Co-Principal investigator. National Science and Technology Council. Title: Establishment of research collaboration and technical service for national human microbiome core facilities. Grant number: NSTC 114-2740-B-A49-003-.
  • 2025/05-2026/04. Co-Principal investigator. National Science and Technology Council. Title: The study of Akkermansia muciniphilaand related metabolites as a biomarker or an adjuvant therapy for hepatocellular carcinoma (II). Grant number: NSTC 114-2321-B-A49-004-.
  • 2025/01-2025/12.  Principal investigator. KMU-NYCU joint grant. Exploring the metabolites of probiotics isolated from Taiwanese to evaluate their potential future. Grant number: NYCUKMU-114-I004.
  • 2025/01-2025/12. Co-Principal investigator. Taipei City Hospital. Investigation of the role of gut microbiota in patients with primary premature ejaculation disorder and its effect on dapoxetine response. Grant number: TBD.
  • 2025/01-2025/12. Principal investigator.Industry-academia collaboration grant. Title:  Drug testing using an interstitial cystitis rat model. Grant number: 114A140063.
  • 2025/01-2025/12. Principal investigator. CGMH-NYCU Joint Research Program. Title: Exploring the potential of low-energy shock waves and bacteriophages in the treatment of recurrent urinary tract infections (II): In vivoGrant number: 114W094004.
  • 2025/01-2025/12. Co-Principal investigator. Taipei Tzu Chi Hospital research grant. Title: Study alternative mechanisms of Staphylococcus lugdunensis against lugdunin. Grant number: TBD.
  • 2025/01-2025/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title: Role of urinary microbiome in kidney calcium oxalate stone formation. Grant number: TBD.
  • 2025/01-2025/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title: Characterization of plasmids carrying carbapenemase genes in carbapenem-resistant Klebsiella pneumoniaeand Escherichia coli isolated from urinary tract infection and bacteremia patients. Grant number: V114C-075.
  • 2025/01-2025/12. Co-Principal investigator. Taoyuan General Hospital research grant (Ministry of Health and Welfare). Title: Investigation of the effects of carbapenemase-siderophore-carrying plasmids from Escherichia coliand Klebsiella pneumoniae on bacterial antimicrobial resistance and virulence. Grant number: PTH114126.
  • 2025/01-2025/12. Co-Principal investigator. Taoyuan General Hospital research grant (Ministry of Health and Welfare). Title: Investigation of the antibiotic resistance, virulence-associated genes, and phenotypes among different species within the Klebsiella pneumoniaespecies complex. Grant number: PTH-114012.
  • 2025/01-2025/12. Co-Principal investigator. National Taiwan University Hospital research grant (Hsin-Chu branch). Title: Exploring the characteristics of hypervirulent and carbapenem-resistant Pseudomonas aeruginosa (I): phenotypic and genotypic analysis. Grant number: 114-HCH064.
  • 2024/12. Principal investigator.Ministry of Science and Technology Research Promotion Center for Life Sciences. 2024 Taiwan Society for Microbiology Annual conference.
  • 2024/08-2028/07. Principal investigator.Industry-academia collaboration grant (Biomedical Industry Ph.D. Program, NYCU). Title:  Development of next-generation probiotic products with enhanced metabolic disease improvement efficiency. Grant number: 113A140106.
  • 2024/08-2025/07. Co-Principal investigator. En Chu Kong Hospital research grant. Title: Investigation of the evolution of carbapenem-resistant Escherichia coliin the host and its association with recurrent infections (second year). Grant number: ECKH_W11303.
  • 2024/08-2027/07. Principal investigator. National Science and Technology Council (Excellent Young Scholars Fund). Title: Development of novel indolenine-substituted pyrazole small molecules to combat multidrug-resistant staphylococcal infections and investigation of their antibacterial and anti-biofilm mechanisms. Grant number: 113-2628-B-A49-011-MY3.
  • 2024/08-2025/07. Co-Principal investigator. National Science and Technology Council. Title: Combating Carbapenem Resistance in Klebsiella pneumoniaeComplex and Enterobacteriaceae Complex: Taiwan’s Diverse Strategies. Grant number: 113-2314-B-002-129-.
  • 2024/08-2025/07. Co-Principal investigator. National Science and Technology Council. Title: Investigation of the anti-lugunin mechanism of Staphylococcus lugdununsis. Grant number: 113-2320-B-182A-014-.
  • 2024/06-2025/02. Principal investigator. Ministry of Education. Title: The New Southbound Policy: Overseas Internship Program. Grant number: 113005400N02.
  • 2024/05-2025/04. Co-Principal investigator. National Science and Technology Council. Title: Establishment of research collaboration and technical service for national human microbiome core facilities. Grant number: NSTC 113-2740-B-A49-003-.
  • 2024/05-2025/04. Co-Principal investigator. National Science and Technology Council. Title: The study of Akkermansia muciniphilaand related metabolites as a biomarker or an adjuvant therapy for hepatocellular carcinoma (I). Grant number: NSTC 113-2321-B-A49-014-.
  • 2024/01-2024/12. The Higher Education Sprout Project of the National Yang Ming Chiao Tung University and Ministry of Education (MOE), Taiwan.
  • 2024/01-2024/12. Principal investigator. CGMH-NYCU Joint Research Program. Title: Exploring the potential of low energy shock waves and bacteriophages in the treatment of recurrent urinary tract infections (I): In vitroGrant number: CGMH-NYCU-113-CORPG8P0211.
  • 2024/01-2024/12. Co-Principal investigator. National Taiwan University Hospital research grant (Hsin-Chu branch). Title: Isolation and characterization of lytic bacteriophages targeting carbapenem-resistant EnterobacterGrant number: 113-HCH057.
  • 2024/01-2024/12. Co-Principal investigator. Research Project of Shin Kong Wu Ho-Su Memorial Hospital. Title: Screening and investigation of antibacterial and antivirulence botanical compounds. Grant number: 2024SKHAND011.
  • 2024/01-2024/12. Co-Principal investigator. Research Project of Shin Kong Wu Ho-Su Memorial Hospital. Title: Investigation of the in vitroevolution of Acinetobacter baumannii under carbapenem-selected stress. Grant number: 2024SKHAND009.
  • 2024/01-2024/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title: To investigate the evolution of pathogen within host and its pathogenesis of recurrent urinary tract infection (II). Grant number: V113C-200.
  • 2024/01-2024/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title: The change of saliva microbiota after interventional sialendoscopy in sialolithiasis patients. Grant number: V113C-192.
  • 2024/01-2024/12. Principal investigator. Yen Tjing Ling Medical Foundation, Taiwan. Title: Characterization of colistin resistance mechanisms in colistin-nonsusceptible  pneumoniae and the role(s) of mcr-carrying plasmids in its pathogenesis. Grant number: CI-113-29.
  • 2023/12-2024/11. Principal investigator.Company industry-academia collaboration grant. Title: Isolation, characterization, and product development of probiotics with potential applications (I). Grant number: 112A40114Y.
  • 2023/10-2024/09. Principal investigator.Company industry-academia collaboration grant. Title: Isolation and characteristics of probiotics with potential applications for improving the gastrointestinal health of animals (I). Grant number:  112A40105Y.
  • 2023/10-2025/12. The Higher Education Sprout Project of the National Yang Ming Chiao Tung University and Ministry of Education (MOE), Taiwan.
  • 2023/08-2024/07. Co-Principal investigator. National Science and Technology Council. Title: Multi-faceted analysis of the evolution and drug resistance of endemic uropathogens: a 24-year longitudinal research from a Southern Taiwan Medical Center. Grant number: 112-2314-B-006-060-.
  • 2023/08-2026/07. Principal investigator. National Science and Technology Council. Title: Multi-faceted analysis of the evolution of Escherichia coli within-host and its interaction with microbiota to explore the mechanisms of recurrent urinary tract infections. Grant number: 112-2320-B-A49-045-MY3.
  • 2023/08-2026/07. Co-Principal investigator. National Science and Technology Council. Title: Effects of Low Energy Shock Waves on urinary tract bacteria- in vitroand in experimental cystitis model in rats. Grant number: NSTC 112-2314-B-182A-135-MY3.
  • 2023/08-2024/07. Co-Principal investigator. En Chu Kong Hospital research grant. Title: Investigation of the evolution of carbapenem-resistant Escherichia coli in the host and its association with recurrent infections. Grant number: ECKH_W11201.
  • 2023/06-2023/09. Principal investigator. Ministry of Education. Title: The New Southbound Policy: Overseas Internship Program. Grant number: 111005400N01.
  • 2023/05-2024/04. Co-Principal investigator. National Science and Technology Council. Title: Establishment of research collaboration and technical service for national human microbiome core facilities. Grant number: NSTC 112-2740-B-A49-002-.
  • 2023/03-2024/02. Principal investigator.Company industry-academia collaboration grant. Title: Isolation and characterization of probiotics with potential applications for the prevention of vaginal infections (I). Grant number:  112A40071Y.
  • 2023/03-2024/02. Co-Principal investigator. Chang Gung Medical Foundation CMRP grant. Title: Characterization of lugdunin activity produced by Staphylococcus lugdunensisisolates from 2003-2020 in Chang Gung Memorial Hospital: epidemiology, antibacterial activity, association with different genotypes, and gene regulation. Grant number: CMRPG3N0091.
  • 2023/01-2023/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title:  Investigation of within-host bacterial evolution and pathogenesis in polymicrobial urinary tract infections. Grant number: V112C-203.
  • 2023/01-2023/12. Principal investigator. Yen Tjing Ling Medical Foundation, Taiwan. Title: Characterization of uropathogenic Escherichia coli in different phylogenetic groups. Grant number: CI-112-19.
  • 2023/01-2023/12. Co-Principal investigator. Taipei Veterans General Hospital research grant. Title: To investigate the evolution of pathogen within host and its pathogenesis of recurrent urinary tract infection. Grant number: V112C-208.
  • 2022/08-2025/07. Co-Principal investigator. National Science and Technology Council. Title: The effects of testicular microenvironment on spermatogenesis in men with non-obstructive azoospermia – Analysis of testicular steroidogenesis patterns and metaproteomics of testicular bacteria microbiome. Grant number: MOST 111-2314-B-075-044-MY3.
  • 2022/08-2023/07. Co-Principal investigator. En Chu Kong Hospital research grant. Title: Investigation of the phenotypic and genomic evolution of carbapenem-resistant Escherichia coliin the host. Grant number: ECKH_W11105.
  • 2022/08-2023/07. Co-Principal investigator. Chang Gung Medical Foundation CMRP grant. Title: Characterization of an endemic Staphylococcus lugdunensis type 6 in a  medical center. Grant number: CMRPG3M1041.
  • 2022/08. Principal investigator.Ministry of Science and Technology Research Promotion Center for Life Sciences. 2022 26th bacteriology conference.
  • 2022/06-2022/05. Principal investigator.BXB company industry-academia collaboration grant. Title: Isolation and characterization of probiotics with potential applications. Grant number: TBC
  • 2021/10-2022/09. Principal investigator.BENED Biomedical company industry-academia collaboration grant. Title: The role(s) of probiotics on anti-Helicobacter pylori activity and its mechanisms (II). Grant number: YM110J063.
  • 2021/08-2022/07. Principal investigator.Ministry of Science and Technology, Republic of China, Taiwan. Title: Investigate the evolution of Escherichia coli within host and its pathogenesis of recurrent urinary tract infection. Grant number: 110-2320-B-A49A-524-.
  • 2021/08-2022/07. Co-Principal investigator. Chang Gung Medical Foundation CMRP grant. Title: Determination of the association of CRISPR-Cas system with oxacillin susceptibility, MLST sequence types, and virulence in Staphylococcus lugdunensis. Grant number: CMRPG3L0631.
  • 2021/01-2021/12. Principal investigator. National Yang-Ming University-Far Eastern Memorial Hospital Joint Research Program, Taiwan. Title: Characterization of carbapenem-non-susceptible Acinetobacterisolated from patients with bloodstream infection. Grant number: 110DN14.
  • 2021/01-2021/12. Principal investigator. Yen Tjing Ling Medical Foundation, Taiwan. Title: Characterization of  coliisolated from patients with recurrent urinary tract infections. Grant number: CI-110-13.
  • 2020/10-2021/10. Principal investigator. Ministry of Science and Technology, Republic of China, Taiwan. Title: Increasing the international visibility of Taiwan society of microbiology. Grant number: 109-2926-I-010-505.
  • 2020/10-2021/09. Co-Principal investigator. Chang Gung Medical Foundation CMRP grant. Title: Determination of oxacillin susceptibility and SCCmecstructure of predominant sequence type 3, 6, and 27 Staphylococcus lugdunensis in Taiwan. Grant number: CMRPG3K1421.
  • 2020/08-2021/07. Principal investigator. BENED Biomedical company industry-academia collaboration grant. Title: The role(s) of probiotics on anti-Helicobacter pyloriactivity and its mechanisms. Grant number: YM109C036.
  • 2020/08-2022/07. Co-Principal investigator. En Chu Kong Hospital research grant.  Title: Molecular characterization of carbapenem-resistant Enterobacteriaceaein a regional teaching hospital in Taiwan, 2011-2019. Grant number: ECKH_W10901 & ECKH_W11001.
  • 2020/08-2023/07. Principal investigator. Ministry of Science and Technology, Taiwan. Title: Characterization of the role(s) of PASTA kinase-mediated signaling pathways in resistance of Staphylococcus aureus to β-lactam antibiotics. Grant number: 109-2320-B-010 -036 -MY3.
  • 2019/10-2020/10. Principal investigator. Ministry of Science and Technology, Taiwan. Title: Connect American and Taiwan societies for microbiology to promote the international visibility of microbiology research in Taiwan . Grant number:108-2911-I-010-508.
  • 2017/10-2019/10. Principal investigator. Postdoctoral Research Abroad Program, Ministry of Science and Technology, Taiwan. Title: Characterization of Listeria monocytogenes CFPTS gene cluster in central nervous systemic infection. Grant number: 106-2917-I-564-070.
 

我們致力於了解細菌的致病機轉、抗生素抗藥性、菌相作用與藥物開發。研究主要聚焦於三大領域：細菌致病機制的基礎研究、抗生素抗藥性機制，以及應用微生物學，特別是小分子治療藥物的開發。以下是我們於過去五年（2020–2025年）在這些領域中的研究成果總結：

一、基礎研究: 自2020年至2025年，我的研究聚焦於多種人類病原菌的生理與致病機制，特別著重於基因調控與代謝途徑。在幽門螺旋桿菌（Helicobacter pylori）中，我們揭示了CsrA如何協調鞭毛組裝與宿主互作。我們進一步發現受CsrA調控的Jhp0106可能為一種參與鞭毛形成與菌體定殖的醣基轉移酶（Helicobacter. 2021 Apr;26(2):e12787）。透過生物資訊分析，我們也鑑定出Jhp0417與Jhp0106可能皆參與幽門螺旋桿菌的鞭毛生合成。我們接著利用TRIzol、甲醇與MTBE等萃取方法進行untargeted metabolomics與lipidomics，分析jhp0417突變株與野生型菌株，結果顯示TRIzol可有效自單一樣本中同時萃取代謝物與脂質（Talanta. 2023 Jun 1;258:124416）。目前我們正深入此研究，透過多體學深入探討CsrA調控網絡機制。總結來說，這些研究有助於加強我們對細菌致病機轉的了解，並為未來治療策略提供潛在研究目標。

二、抗生素抗藥性研究: 我的抗藥性研究整合了診斷技術開發、抗藥性基因監測，以及可移動遺傳核酸片段的追蹤。我們驗證了mCIM與eCIM檢測carbapenemase的準確性，並指出多種carbapenemase共攜帶時可能影響檢測表現（BMC Microbiol. 2020 Oct 17;20(1):315）。對於Staphylococcus lugdunensis，培養稀釋法比其他方法更能準確評估其對oxacillin的敏感性（J Microbiol Immunol Infect. 2022 Apr;55(2):234-240）。基因體流行病學研究顯示，多重抗藥性的大腸桿菌、克雷伯氏肺炎菌、與鮑氏不動桿菌廣泛攜帶carbapenemase、mcr與qnr等抗藥基因（Front Microbiol. 2022 Mar 11;13:703113；J Glob Antimicrob Resist. 2022 Sep;30:241-248；Epidemiol Infect. 2023 Sep 7;151:e155；J Infect Public Health. 2024 Mar;17(3):457-463；J Microbiol Immunol Infect. 2024 Apr;57(2):288-299；Microbiol Spectr. 2024 Jun 4;12(6):e0038224；J Infect Public Health. 2024 Dec;17(12):102588；Int J Antimicrob Agents. 2025 Aug;66(2):107515）。這些抗藥基因也常位於能提升細菌致病力的質體上，我們已證實透過質體轉移後，細菌對Galleria mellonella的致病力顯著上升（BMC Microbiol. 2022 Jun 6;22(1):150；Infect Genet Evol. 2023 Jun;110:105420）。此外，我們發現從年長病人分離的大腸桿菌株，其抗藥性普遍高於兒童或年輕成人的菌株（J Microbiol Immunol Infect. 2022 Apr;55(2):249-256），而且大腸桿菌不同的phylogroup其致病性也有所差異，其中B2群菌株較具致病性（Infect Genet Evol. 2023 Oct;114:105493）。值得注意的是，近半數反覆性泌尿道感染病人感染的是同一clone，我們目前正針對宿主體內的菌株演化與致病性變化進行研究（BMC Microbiol. 2023 Mar 30;23(1):90；Gut Pathogens, In revision）。在S. lugdunensis中，我們探討了CRISPR-Cas系統類型與抗藥性、序列型與lugdunin產量之間的關聯，反映出抗藥性與細菌防禦機制間的複雜互動（Microbiol Spectr. 2021 Dec 22;9(3):e0124721；J Microbiol Immunol Infect. 2023 Apr;56(2):292-298；Microbiol Spectr. 2023 Sep 21;11(5):e0129823；J Microbiol Immunol Infect. 2024 Apr;57(2):278-287）。最近，我們聚焦於具高度毒力與極度抗藥性的菌株。研究發現ST2型A. baumannii株展現更強的致病性與抗藥性（Int J Antimicrob Agents. 2024 Dec;64(6):107358），凸顯其為新興高風險病原體的威脅。我們正針對多種具類似高風險特性的菌種展開相關研究。

三、應用微生物學: 我的應用微生物學研究致力於將基礎研究成果轉譯為治療策略，聚焦於益生菌、小分子抗菌物質與噬菌體療法。我們鑑定出Lactiplantibacillus pentosus SLC13與其他本土菌株具備抗病原菌與免疫調節潛力（BMC Microbiol. 2022 Nov 21;22(1):277；BMC Microbiol. 2024 Mar 11;24(1):85），目前正探討其抑菌的分子機制。針對革蘭氏陽性病原菌，我們研究了產生lugdunin的S. lugdunensis，發現其抗菌活性可能受CRISPR-Cas系統調控，後續研究正進一步探討其生合成的調節機制（Microbiol Spectr. 2023 Sep 21;11(5):e0129823）。與馬來亞大學合作，我們評估了indolenine衍生物4e，並證實其在細胞與動物模型中具抗生物膜活性（Antimicrob Agents Chemother. 2025 Jul 23:e0019925），後續也正評估其其他衍生物與作用機制。此外，我們亦證實低能量震波療法可有效治療UPEC引起的大鼠膀胱炎（Int Urol Nephrol. 2025 Jan;57(1):49-61）。在噬菌體療法方面，我們成功分離出針對carbapenem-resistant Enterobacter cloacae的裂解型噬菌體，於蠕蟲與小鼠感染模型中均顯著提升存活率（Microbiology Spectrum, In revision）。在環境微生物學領域，我們報導經工程設計的Bi₂Te₃奈米片於海洋防汙應用中展現優異的haloperoxidase活性（Small. 2024 Oct;20(43):e2401929）。近期，我們已啟動針對Akermansia muciniphila與Bacteroides等次世代益生菌的研究，探討其於腸肝軸調控與酒精性肝病等代謝疾病治療上的潛力。這些研究顯示我們自菌株篩選至轉譯應用於微生物治療產品開發的完整研究鏈。

實驗室成員

PhD students

  • Jazon Harl Hidrosollo
  • Yen-Zheng Zhang
  • Pei-Yun Kuo
  • Tran Thi Dieu Thuy
  • Tran Thi Thuy Duong
  • Carl Jay Ballena Bregente 
  • Pek Kee Chen
  • Pei-Chun Tu
  • Ya-Yu Zheng
  • Nevia Longjam

Master students

  • Alonso Enrique Africa
  • Tzu-Lin Chang
  • Jia-Yu Xie
  • Laishram Yashmine Devi
  • Yi-Ru Boey
  • Rong-Xuan Wu
  • Nguyen Van Tat Thanh
  • Yi-Chien Kao
  • Shen-Shawn Ruan
  • Ramgie Micaller Bartolata
  • 吳佳倩

Undergraduate students

  • 李佳芮
  • 孫于然
  • 蕭仲甫
  • 林諺豐
  • 鄭宇均
  • 高璇

實驗室照片